FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Pacific Biosciences of California, Inc. Stock AnalysisComprehensive stock analysis for Pacific Biosciences of California, Inc. (PACB) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPACB
PACB
Pacific Biosciences of California, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PACB
Home🔹Stocks🔹Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.

🇺🇸PACB•NASDAQ

Pacific Biosciences of California, Inc.

🇺🇸PACB•NASDAQ
Market cap
$403.78M
Sentiment

Your view on PACB

Mkt Cap
$403.78M
Sentiment
Your view
PACB
Pacific Biosciences of California, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PACB
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Pacific Biosciences of California, Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Christian O. Henry
Headquarters
1305 O’Brien Drive, Menlo Park, CA, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Christian O. Henry
Headquarters
1305 O’Brien Drive, Menlo Park, CA, US
Description

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems.

The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.

It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.

The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies.

It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation.

The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Pacific Biosciences of California, Inc., and the rating behind it. PACB last traded at $1.30; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Pacific Biosciences of California, Inc.. Starting points for Pacific Biosciences of California, Inc.: EPS -$0.42, beta 2.31 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Pacific Biosciences of California, Inc.. Pacific Biosciences of California, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Pacific Biosciences of California, Inc.. Trailing twelve-month EPS for Pacific Biosciences of California, Inc. stands at -$0.42. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Pacific Biosciences of California, Inc.. Pacific Biosciences of California, Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Pacific Biosciences of California, Inc. valued side by side against its closest peers. Pacific Biosciences of California, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Pacific Biosciences of California, Inc., and how their positions are changing. At a $403.8M market value, institutional positions materially move Pacific Biosciences of California, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Pacific Biosciences of California, Inc. executives and directors. Shares of Pacific Biosciences of California, Inc. have traded between $0.85 and $2.46 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Pacific Biosciences of California, Inc.. Pacific Biosciences of California, Inc. is a $403.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Pacific Biosciences of California, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Pacific Biosciences of California, Inc.. Coverage tracks Pacific Biosciences of California, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • BFLY — Butterfly Network, Inc.
  • DNA — Ginkgo Bioworks Holdings, Inc.
  • DRIO — DarioHealth Corp.
  • FLGT — Fulgent Genetics, Inc.
  • IART — Integra LifeSciences Holdings Corporation
  • IOVA — Iovance Biotherapeutics, Inc.
  • OFIX — Orthofix Medical Inc.

More Medical - Devices companies

  • VRSYF — VMS Rehab Systems, Inc.
  • VTAK — Catheter Precision, Inc.
  • VTRLY — Vitrolife AB (publ)
  • VVOS — Vivos Therapeutics, Inc.
  • VYCO — Vycor Medical, Inc.
  • WILLF — Demant A/S
  • WILYY — Demant A/S
  • WLSI — Wellstar International, Inc.
  • XAIR — Beyond Air, Inc.
  • XCRP — Xcorporeal, Inc.
  • XTNT — Xtant Medical Holdings, Inc.
  • XVIPF — Xvivo Perfusion AB (publ)

ETFs holding Pacific Biosciences of California, Inc.

  • ARKG — ARK Genomic Revolution ETF (0.74%)
  • EVNT — AltShares Event-Driven ETF (0.72%)
  • QQQS — Invesco NASDAQ Future Gen 200 ETF (0.44%)

News

Latest Market News